Bayer: lymphoma drug wins FDA priority review.

(CercleFinance.com) - Bayer said on Wednesday that the US Food and Drug Administration (FDA) has granted a priority review designation for copanlisib in the treatment of relapsed or refractory follicular lymphoma.


The fast-track status on the intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor deals with patients who have received at least two therapies already.

Follicular lymphoma is the most common subtype of indolent non-Hodgkin's lymphoma.

With the priority review, the FDA aims to complete its review within six months, compared to 10 months under standard review.

Copyright (c) 2017 CercleFinance.com. All rights reserved.